Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: A 12-month, randomized, double-blind, placebo-controlled trial

Scandinavian Journal of Rheumatology

Volumn 41, Issue 4, 2012, Pages 260-266

  Hakala, M ^a   Kroger H ^b   Valleala, H ^c   Hienonen Kempas, T ^d   Lehtonen Veromaa, M ^e   Heikkinen, J ^f   Tuomiranta, T ^g   Hannonen, P ^h   Paimela, L ⁱ  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d Roche Oy   (Finland)

^e Pulssi Medical Centre   (Finland)

^f OULU DEACONESS INSTITUTE   (Finland)

^g Tampere City Hospital   (Finland)

^h JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

ⁱ ORTON Invalid Foundation   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCIUM; COLLAGEN TYPE 1; IBANDRONIC ACID; PLACEBO; PREDNISONE; PROCOLLAGEN C PROTEINASE; VITAMIN D;

ACUTE PANCREATITIS; ACUTE PYELONEPHRITIS; ADULT; AGRANULOCYTOSIS; ANEMIA; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE TURNOVER; CONCUSSION; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ERYSIPELAS; FEMALE; FEMUR NECK; FOLLICLE CENTER LYMPHOMA; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HIP; HIP FRACTURE; HUMAN; INTOXICATION; LUMBAR SPINE; LUNG EMBOLISM; LYMPHOMA; MAJOR CLINICAL STUDY; PNEUMONIA; POSTMENOPAUSE; PRIORITY JOURNAL; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC DISEASE; SEPSIS; TONGUE CANCER; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE; RHEUMATIC DISEASES; TREATMENT OUTCOME;

EID: 84863952216     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2012.664647     Document Type: Article

References (20)

1. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102:274-82. (Pubitemid 28335186)
2. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006;147:5592-9. (Pubitemid 44833476)
3. Canalis E. Effect of glucocorticoids on type I collagen synthesis, alkaline phosphatase activity, and deoxyribonucleic acid content in cultured rat calvariae. Endocrinology 1983;112:931-9.
4. Advani S, Lafrancis D, Bogdanovic E, Taxel P, Raisz LG, Kream BE. Dexamethasone suppresses in vivo levels of bone collagen synthesis in neonatal mice. Bone 1997;20:41-6. (Pubitemid 27046018)
5. van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:3104-12. (Pubitemid 44622079)
6. Huusko TM, Korpela M, Karppi P, Avikainen V, Kautiainen H, Sulkava R. Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland. Ann Rheum Dis 2001;60:521-2. (Pubitemid 32417428)
7. Dolan AL, Moniz C, Dasgupta B, Li F, Mackintosh C, Todd P, et al. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum 1997; 40:2022-9. (Pubitemid 27494663)
8. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister RF, Zimmerman B, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96:115-23. (Pubitemid 24070529)
9. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62:1515-26.
10. Emkey RD, Ettinger R. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006; 119:S18-24.
11. Bonnick SL, Silverman S, Tanner SB, Martens M, Bachmann G, Kohles JD, et al. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate. J Womens Health (Larchmt) 2009;18:935-43.
12. Osteoporosis (online). Current Care guideline. Working group set up by the Finnish Medical Society Duodecim, Finnish Endocrine Society and Finnish Gynaecological Association. Helsinki: Finnish Medical Society Duodecim, 2006. Available from: www.kaypahoito.fi/web/english/home.
13. Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, doubleblind, placebo-controlled trial. Osteoporos Int 2006;17:716-23.
14. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-85.
15. Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen M, et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 2009;36:1705-14.
16. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919-23.
17. Lems WF. Bisphosphonates and glucocorticoids: effects on bone quality. Arthritis Rheum 2007;56:3518-22. (Pubitemid 350100684)
18. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003;14:801-7. (Pubitemid 37462129)
19. Reginster JY. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 2011;71:65-78.
20. Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66:1560-7. (Pubitemid 350205441)